Cumberland Pharmaceuticals (CPIX) Competitors $4.76 +0.23 (+5.08%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.64 -0.12 (-2.52%) As of 04/17/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CPIX vs. NKTR, ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Cumberland Pharmaceuticals vs. Nektar Therapeutics Assembly Biosciences Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Nektar Therapeutics (NASDAQ:NKTR) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Is NKTR or CPIX more profitable? Cumberland Pharmaceuticals has a net margin of -29.54% compared to Nektar Therapeutics' net margin of -180.70%. Cumberland Pharmaceuticals' return on equity of -9.50% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-180.70% -173.28% -46.31% Cumberland Pharmaceuticals -29.54%-9.50%-3.19% Do institutionals and insiders believe in NKTR or CPIX? 75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 3.7% of Nektar Therapeutics shares are held by company insiders. Comparatively, 44.8% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor NKTR or CPIX? Nektar Therapeutics received 450 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 70.73% of users gave Nektar Therapeutics an outperform vote while only 41.69% of users gave Cumberland Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63870.73% Underperform Votes26429.27% Cumberland PharmaceuticalsOutperform Votes18841.69% Underperform Votes26358.31% Which has stronger valuation and earnings, NKTR or CPIX? Cumberland Pharmaceuticals has lower revenue, but higher earnings than Nektar Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$98.43M1.20-$276.06M-$0.59-1.08Cumberland Pharmaceuticals$37.87M1.76-$6.28M-$0.47-10.13 Does the media favor NKTR or CPIX? In the previous week, Nektar Therapeutics had 2 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 3 mentions for Nektar Therapeutics and 1 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.81 beat Nektar Therapeutics' score of 0.37 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Nektar Therapeutics Neutral Cumberland Pharmaceuticals Positive Do analysts prefer NKTR or CPIX? Nektar Therapeutics currently has a consensus price target of $4.50, suggesting a potential upside of 607.10%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Cumberland Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Cumberland Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, NKTR or CPIX? Nektar Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. SummaryNektar Therapeutics beats Cumberland Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get Cumberland Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPIX vs. The Competition Export to ExcelMetricCumberland PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.49M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-6.186.9521.9417.81Price / Sales1.76231.03380.9597.68Price / Cash8.6165.6738.2634.64Price / Book2.435.936.453.98Net Income-$6.28M$143.22M$3.22B$247.81M1 Month Performance-6.11%-13.56%-9.76%-7.91%1 Year Performance197.50%-8.89%11.49%1.53% Cumberland Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPIXCumberland Pharmaceuticals0.9799 of 5 stars$4.76+5.1%N/A+188.5%$66.49M$37.87M-6.1880Short Interest ↓News CoveragePositive NewsGap DownNKTRNektar Therapeutics3.93 of 5 stars$0.49-11.1%$4.92+902.6%-51.8%$91.27M$98.43M-0.58220Analyst ForecastHigh Trading VolumeASMBAssembly Biosciences3.8979 of 5 stars$8.63-0.9%$33.00+282.4%-24.8%$64.75M$28.52M-1.28100Short Interest ↓LLYEli Lilly and Company4.794 of 5 stars$722.03-2.2%$1,009.72+39.8%+12.8%$684.61B$45.04B61.6639,000News CoverageGap UpJNJJohnson & Johnson4.5085 of 5 stars$150.47-1.8%$171.33+13.9%+8.0%$362.60B$88.82B22.63152,700Earnings ReportDividend IncreaseAnalyst ForecastOptions VolumeAnalyst RevisionHigh Trading VolumeABBVAbbVie4.9003 of 5 stars$186.11-0.5%$211.45+13.6%+4.9%$329.22B$56.33B77.5550,000Upcoming EarningsEx-DividendAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsHigh Trading VolumeMRKMerck & Co., Inc.4.9993 of 5 stars$81.11-0.4%$117.12+44.4%-37.7%$205.80B$64.17B12.0569,000Upcoming EarningsAnalyst ForecastHigh Trading VolumePFEPfizer4.9986 of 5 stars$22.64-1.4%$31.92+41.0%-12.8%$128.40B$63.63B16.0683,000High Trading VolumeBMYBristol-Myers Squibb4.7282 of 5 stars$55.18-0.2%$57.86+4.9%+1.9%$112.27B$48.30B-12.4834,300Upcoming EarningsShort Interest ↓Analyst RevisionNews CoveragePositive NewsZTSZoetis4.5791 of 5 stars$149.03-1.8%$215.90+44.9%-2.9%$66.73B$9.26B27.2414,100News CoveragePositive NewsRPRXRoyalty Pharma4.5157 of 5 stars$31.03-0.3%$41.60+34.1%+16.5%$17.89B$2.26B21.4080News CoveragePositive News Related Companies and Tools Related Companies NKTR Alternatives ASMB Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives RPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPIX) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
